Addex Therapeutics products

Dipraglurant is a novel orally available highly selective metabotropic glutamate receptor subtype 5 negative allosteric modulator (mGlu5 NAM) which has completed Phase 1 and demonstrated efficacy in a Phase 2a  proof of concept study for the treatment of levodopa-induced dyskinesia associated with Parkinson’s disease (PD-LID).  This is a disease with significant commercial opportunity as improved therapies are needed.

Our partner, Indivior, has licensed worldwide rights to our GABAB PAM program and is responsible for all development, manufacture and commercialization of any selected GABAB PAM drug candidates. Under the agreement, we are responsible for executing a research program funded by Indivior to discover novel drug candidates. Indivior has the right to select GABAB PAM drug candidates from our research program.

Our license agreement with Indivior provides for a funded research program, under which we have the right to select drug candidates for exclusive development in certain indications outside of SUD. We plan to develop our selected drug candidates in CMT1a, chronic cough and pain. These indications have been validated with baclofen, an orthosteric agonist of GABAB and present a significant unmet medical need and commercial opportunity. We are in clinical candidate selection phase and expect IND enabling studies to be initiated in 2023.

mGlu2 NAM for the treatment of mild neurocognitive disorders, or mNCD. We are developing mGlu2 NAM as a novel orally available treatment for mNCD associated with Alzheimer’s disease, Parkinson’s disease and depressive disorders. The program is in clinical candidate selection phase and we expect to enter IND enabling studies early in H2 2023.

We are developing metabotropic glutamate receptor subtype 7, or mGlu7 NAM as a novel orally available treatment to reduce fear memory in PTSD. This is a disorder that can lead to intense fear and anxiety. Current medication is unspecific and ineffective, with a number of side effects. By selectively targeting mGlu7 with NAMs, the brain circuitries involved in fear and anxiety can be more precisely modulated, potentially resulting in a more focused response and fewer side effects than current therapeutic approaches.

We are developing muscarinic acetylcholine receptor subtype 4 positive allosteric modulator, or M4 PAM, as a novel orally available treatment for schizophrenia & other psychosis.  Schizophrenia affects approximately 24 million people worldwide, requiring lifelong treatment to reduce severe impact on their everyday life. The market for antipsychotics represents over $7B annual sales in the main markets, growing approximately 3.5% per year. There is a significant need for new treatment options, as currently available antipsychotics, that largely act via direct blockade of dopaminergic neurotransmission, fail to reduce negative symptoms and alleviate cognitive abnormalities, while also being linked to poor tolerability which leads to discontinuation of treatment.

We are developing mGlu4 PAM as a novel orally available treatment for Parkinson`s disease. We are currently optimizing multiple chemical series of highly selective mGlu4 PAMs with compounds in early lead optimization.

mGlu3 PAM for the treatment of neurodegenerative disorders. We are developing mGlu3 PAM as a novel orally available treatment for neurodegenerative disorders. We are currently optimizing multiple chemical series of highly selective mGlu3 PAMs, with compounds in early lead optimization.

Allosteric modulators are an emerging class of orally available small molecule therapeutic agents that may offer a competitive advantage over classical drugs.